STATIN (version 1.0)
Research type
Research Study
Full title
Randomised Controlled Trial with Pravastatin versus Placebo for PreventIon of Pre-eclampsia
IRAS ID
191828
Contact name
Kypros Nicolaides
Contact email
Sponsor organisation
Fundación para la Formación e Investigación Sanitaria (FFIS)
Eudract number
2015-005130-22
ISRCTN Number
ISRCTN17787139
Duration of Study in the UK
2 years, 0 months, 0 days
Research summary
The placenta (afterbirth) is responsible for providing food and oxygen to the fetus. When there is a problem with the function of the placenta the fetus may not grow well and the mother can develop high blood pressure (pre-eclampsia). In some cases, it can lead to serious consequences such as kidney and liver damage, convulsions, stroke and death.
There are no effective drug treatments available to prevent or reverse pre-eclampsia. Statins are a group of medicines that can help lower the level of low-density lipoprotein (“bad cholesterol” ) in the blood, and is commonly used in the prevention of cardiovascular disease such as coronary heart disease and stroke. Pre-eclampsia shares similar pathways and risk factors with cardiovascular disease. Recent scientific research suggests that statins can reduce certain placental proteins that are involved in the development of pre-eclampsia. This study aims to investigate the potential beneficial effect of statin for pregnant women at high-risk of developing pre-eclampsia, in preventing complications and improving the outcome for both the mother and the baby.
REC name
London - Riverside Research Ethics Committee
REC reference
16/LO/0024
Date of REC Opinion
4 Jul 2016
REC opinion
Further Information Favourable Opinion